Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
liver fatty acid-binding protein (FABP1) (FABP1)
- Target
- FABP1
- Molecular classification
- Fatty acid-binding protein family, Intracellular lipid-binding protein, Cytosolic protein, Other
01
Overview
Liver fatty acid-binding protein (FABP1) is a cytosolic protein highly expressed in hepatocytes that binds fatty acids, heme, and other hydrophobic molecules, protecting the liver from oxidative damage by sequestering potentially toxic substances. It plays critical roles in fatty acid uptake, metabolism, lipid homeostasis, adaptation to oxidative stress, hepatic regeneration, and may serve as a biomarker of acute or chronic liver injury
- Other names
- L-FABPFABP1hepatic fatty acid-binding proteinliver cytosolic fatty acid-binding protein
02
Mechanism of action
Binds and sequesters hepatotoxins (toxic fatty acids, heme, other porphyrins) in the cytosol to reduce their toxicity; Modulates nuclear signaling via ligand (fatty acid/heme) transfer to transcription factors; Regulates cellular response to oxidative stress
03
Biological functions
Fatty acid binding and transportUptake and metabolism of hydrophobic molecules (fatty acids, heme, bilirubin)Modulation of lipid metabolismCytoprotection against oxidative stress and hepatotoxinsRegulation of cell proliferation in liver regenerationInflammatory response
04
Disease associations
Liver injury (e.g., ischemia-reperfusion injury)Nonalcoholic fatty liver diseaseOxidative stress-related liver damageInflammationInfection (modulation of host response under stress/infection)
05
Safety considerations
N/A (FABP1 is not a therapeutic target of drugs with known on-target toxicity; rather, its deficiency or malfunction may predispose to liver injury)
06
Interacting drugs
No small-molecule drugs are currently approved specifically targeting FABP1 for therapeutic modulation in clinical practice. However, some experimental FABP inhibitors exist; certain hepatotoxic drugs may indirectly interact via FABP1-mediated transport and protection
07
Biomarkers
FABP1 plasma or tissue levels (proposed biomarker for liver injury assessment and prognosis in hepatic disease)FABP5 has been identified as an early biomarker of ferroptosis, another form of regulated cell death relevant to liver injury
Beyond the preview
Go deeper on liver fatty acid-binding protein (FABP1) (FABP1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liver fatty acid-binding protein (FABP1) (FABP1).